Pirbuterol

From WikiProjectMed
Jump to navigation Jump to search
Pirbuterol
Clinical data
Trade namesMaxair
AHFS/Drugs.comConsumer Drug Information
MedlinePlusa601096
Pregnancy
category
  • C
Routes of
administration
Inhalational (MDI)
ATC code
Legal status
Legal status
Identifiers
  • (RS)-6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H20N2O3
Molar mass240.303 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • Oc1ccc(nc1CO)C(O)CNC(C)(C)C
  • InChI=1S/C12H20N2O3/c1-12(2,3)13-6-11(17)8-4-5-10(16)9(7-15)14-8/h4-5,11,13,15-17H,6-7H2,1-3H3 checkY
  • Key:VQDBNKDJNJQRDG-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Pirbuterol (trade name Maxair) is a short-acting β2 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler.

It was patented in 1971 and came into medical use in 1983.[1]

Medical use

Pirbuterol is used in asthma for reversal of acute bronchospasm, and also as a maintenance medication to prevent future attacks. It should be used in patients 12 years of age and older with or without concurrent theophylline and/or inhaled corticosteroid.[2][3]

Mode of action

Pharmacokinetics

After inhalation of doses up to 800 μg (twice the maximum recommended dose) systemic blood levels of pirbuterol are below the limit of assay sensitivity (2–5 ng/ml). A mean of 51% of the dose is recovered in urine as pirbuterol plus its sulfate conjugate following administration by aerosol. Pirbuterol is not metabolized by catechol-O-methyltransferase. The plasma half-life measured after oral administration is about two hours.[2]

Adverse effects

References

  1. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 543. ISBN 9783527607495.
  2. ^ a b "Maxair Autohaler (pirbuterol acetate inhalation aerosol) For Oral Inhalation Only. U.S. Full Prescribing Information". 3M Pharmaceuticals. Northridge, CA 91324. Archived from the original on 20 September 2018. Retrieved 7 March 2016.
  3. ^ Bianchi M, Clavenna A, Bonati M (September 2010). "Inter-country variations in anti-asthmatic drug prescriptions for children. Systematic review of studies published during the 2000-2009 period" (PDF). European Journal of Clinical Pharmacology. 66 (9): 929–36. doi:10.1007/s00228-010-0845-y. PMID 20533030. S2CID 21834280.

External links